Velsipity, containing the active ingredient etrasimod, is a once-daily oral tablet for adults with moderately to severely active ulcerative colitis (UC). Approved by the FDA in October 2023, it was developed by Pfizer and offers an oral alternative to some other UC therapies. Velsipity works to manage the inflammation associated with UC, aiming for symptom improvement and remission.
How Velsipity Works to Reduce Inflammation
Velsipity is a selective sphingosine 1-phosphate (S1P) receptor modulator. By targeting S1P receptors on immune cells, Velsipity limits their movement from lymph nodes to the intestines, thereby reducing inflammation in the colon and rectum.
Clinical Efficacy and Trial Results
The effectiveness of Velsipity was evaluated in the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials involving adults with moderate to severe UC. Results showed higher rates of clinical and steroid-free remission compared to placebo. More detailed information on the clinical trial results can be found on {Link: NCBI Bookshelf https://www.ncbi.nlm.nih.gov/books/NBK607351/}.
Comparison with Other Ulcerative Colitis Treatments
Velsipity is compared to other UC treatments, including other oral S1P receptor modulators and injectable biologics. A comparison table outlines key features such as administration, dosing, mechanism, and speed of action.
| Feature | Velsipity (etrasimod) | Zeposia (ozanimod) | Biologics (e.g., Humira, Remicade) |
|---|---|---|---|
| Administration | Oral tablet, once daily | Oral capsule, once daily (requires titration) | Injection (subcutaneous or intravenous infusion) |
| Dosing | No dose titration required | Requires dose titration over the first week | Typically involves induction and maintenance phases |
| Mechanism of Action | S1P receptor modulator (selective) | S1P receptor modulator | Bind to and block inflammatory proteins like TNF-alpha |
| Primary Advantage | Oral convenience, no titration required | Oral convenience, established treatment | Specific targeting of inflammatory pathways |
| Speed of Action | Can provide improvement in as little as 2 weeks | Also can provide rapid improvement | Varies depending on the specific biologic agent |
Important Safety Information
Before starting Velsipity, medical assessments including CBC, ECG, liver tests, and an eye exam are required. Velsipity is contraindicated for individuals with certain heart conditions, severe liver issues, or during pregnancy. Common side effects include headache, elevated liver enzymes, dizziness, and joint pain. Serious risks include increased infection risk, temporary heart rate slowing (bradyarrhythmia), macular edema, skin cancer, and Posterior Reversible Encephalopathy Syndrome (PRES).
Conclusion
Velsipity (etrasimod) provides a once-daily oral treatment for adults with moderate to severe UC, targeting inflammation via S1P receptor modulation. Clinical evidence supports its effectiveness in achieving remission. Pre-treatment evaluations and monitoring are crucial due to potential risks and side effects. Patients should consult their healthcare provider to see if Velsipity is suitable.
